Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$19.89 - $43.18 $18,060 - $39,207
-908 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$26.75 - $46.02 $24,289 - $41,786
908 New
908 $40,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $606M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Signet Financial Management, LLC Portfolio

Follow Signet Financial Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signet Financial Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signet Financial Management, LLC with notifications on news.